Association Between Proton Pump Inhibitor Use During Early Pregnancy and Risk of Congenital Malformations > Achievement

본문 바로가기

Achievement

Achievement

국외
JAMA NETWORK OPEN
Association Between Proton Pump Inhibitor Use During Early Pregnancy a…
2023
SCI
Ahhyung Choi, Yunha Noh, Han Eol Jeong, Eun-Young

페이지 정보

본문

[Association Between Proton Pump Inhibitor Use During Early Pregnancy and Risk of Congenital Malformations]

 

Importance: Proton pump inhibitors (PPIs) are increasingly used during pregnancy; however, several observational studies have raised concerns about an increased risk of specific types of congenital malformations. 

 

Objective: To examine the association between PPI exposure during early pregnancy and the risk of congenital malformations. 

 

Design, setting, and participants: This population-based cohort study used data from the National Health Insurance Service-National Health Information Database of South Korea (2010-2020); sibling-controlled analyses were conducted to account for familial factors. A total of 2 696 216 pregnancies in women aged 19 to 44 years between June 1, 2011, and December 31, 2019, and their live-born infants were identified. Pregnant women who were exposed to known teratogens or who delivered infants with chromosomal abnormalities or genetic syndromes were excluded. Data on participant race and ethnicity were not collected because the National Health Information Database does not report this information. 

 

Exposures: Proton pump inhibitor use during the first trimester. 

 

Main outcomes and measures: Primary outcomes were major congenital malformations, congenital heart defects, cleft palate, hydrocephalus, and hypospadias. The subtypes of major congenital malformations and congenital heart defects were evaluated as exploratory outcomes. Propensity score fine stratification was used to control for potential confounders, and a weighted generalized linear model was used to estimate relative risks with 95% CIs. 

 

Results: Of 2 696 216 pregnancies (mean [SD] maternal age, 32.1 [4.2] years), 40 540 (1.5%; mean [SD] age, 32.4 [4.6] years) were exposed to PPIs during the first trimester. The absolute risk of major congenital malformations was 396.7 per 10 000 infants in PPI-exposed pregnancies and 323.4 per 10 000 infants in unexposed pregnancies. The propensity score-adjusted relative risks were 1.07 (95% CI, 1.02-1.13) for major congenital malformations, 1.09 (95% CI, 1.01-1.17) for congenital heart defects, 1.02 (95% CI, 0.72-1.43) for cleft palate, 0.94 (95% CI, 0.54-1.63) for hydrocephalus, and 0.77 (95% CI, 0.51-1.17) for hypospadias. In the sibling-controlled analyses, no associations were observed between PPI use and primary outcomes, including major congenital malformations (odds ratio, 1.05; 95% CI, 0.91-1.22) and congenital heart defects (odds ratio, 1.07; 95% CI, 0.88-1.30). A range of sensitivity analyses revealed results that were similar to the main findings. 

 

Conclusions and relevance: In this cohort study, the use of PPIs during early pregnancy was not associated with a substantial increase in the risk of congenital malformations, although small increased risks were observed for major congenital malformations and congenital heart defects; findings from sibling-controlled analyses revealed that PPIs were unlikely to be major teratogens. These findings may help guide clinicians and patients in decision-making about PPI use in the first trimester.

 

Conflict of interest statement

Conflict of Interest Disclosures: Dr Man reported receiving grants from the C.W. Maplethorpe Fellowship, the European Commission Framework Horizon 2020, the Hong Kong Research Grant Council, the Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region, and the National Institute for Health and Care Research (UK) and personal fees from IQVIA outside the submitted work. Dr Shin reported receiving grants from the National Research Foundation of Korea during the conduct of the study and grants from Daiichi Sankyo, GSK, the Ministry of Food and Drug Safety, the Ministry of Health and Welfare, and Pfizer outside the submitted work. No other disclosures were reported.

Total 50건 1 페이지

검색


  • 마더투베이비㈜
  • 대표자 : 한혜지
  • 서울시 중구 퇴계로 50길 12-1 조움빌딩 2층
  • TEL : 02)2272-4737
  • E-mail : twosafe.verified@gmail.com
  • 사업자등록번호 : 794-82-00187
Copyright © mothertobaby.co.kr All rights reserved.